On November 21, 2024 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, reported that it will participate in the following upcoming investor conferences (Press release, Precision Biosciences, NOV 21, 2024, View Source [SID1234648554]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
JonesTrading Virtual Genetic Medicine Day
Date: Monday, November 25, 2024
Time: 11:00 AM ET
Panel Title: Next Generation of Gene Editing; Going Beyond "Cas"
Webcast Link: Register Here
AussieMit
Date: Friday, November 29, 2024
Time: 2:50 PM AEDT
Presentation Title: Emerging Therapies
A live webcast for the JonesTrading Virtual Genetic Medicine Day will also be accessible on Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will be available for approximately 30 days following the event.